Physician profile
Ky H Le
NPI 1073560025
$6,143.82
in general payments reported to CMS, 2019-2025
23 companies · $1,693 in 2025
The $1,693 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $46.49 · 2021: $176 · 2022: $569 · 2023: $1,358 · 2024: $2,194 · 2025: $1,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,136 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,136.49 |
| Education | $108.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $984.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $837.11 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Abbvie INC. | $804.00 | 2021-2025 | |
| Amgen INC. | $717.13 | 2022-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $654.03 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Genzyme Corporation | $524.53 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $494.40 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $177.15 | 2023-2024 | Dupixent |
| Pfizer INC. | $130.87 | 2019-2025 | |
| Insmed, INC. | $130.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $127.22 | 2022-2024 | |
| Harmony Biosciences LLC | $125.00 | 2023 | Wakix |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Tactile Systems Technology INC | $62.46 | 2023 | Entre Plus, Flexitouch Plus |
| E.R. Squibb & Sons, L.L.C. | $48.38 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.49 | 2020 | |
| Tempus Ai, INC | $44.11 | 2024 | Xt Cdx |
| Bioventus LLC | $24.32 | 2025 | Durolane |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.94 | 2024 | Caplyta |
| Revance Therapeutics, INC. | $22.72 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.70 | 2024 | Synjardy, Jardiance |
| Merz North America, INC. | $22.35 | 2024 | |
| Glaxosmithkline, LLC. | $20.49 | 2024 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ky Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.